Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | LPL | P06858 | 3/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.33 |
| ▸ | LIPE | Q05469 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26921826 | 0.87 | EGFR (0.32) | EGFR | |
| SCHEMBL21751380 | 0.84 | LPL (0.36) | EGFRLPLLIPGLIPEJAK2 | |
| SCHEMBL22690803 | 0.82 | JAK2 (0.31) | EGFRJAK2BTK | |
| SCHEMBL29960842 | 0.80 | EGFR (0.45) | EGFRLPLLIPGJAK2BTK | |
| SCHEMBL1642097 | 0.80 | EGFR (0.45) | EGFRLPLLIPGJAK2BTK | |
| SCHEMBL26920866 | 0.79 | LPL (0.33) | LPLLIPG | |
| SCHEMBL24773231 | 0.78 | LPL (0.42) | EGFRLPLLIPGJAK2BTK | |
| SCHEMBL21752122 | 0.77 | EGFR (0.35) | EGFRLPLLIPGJAK2BTK | |
| SCHEMBL26111348 | 0.77 | ALDH1A1 (0.39) | EGFRLPLLIPGJAK2BTK | |
| SCHEMBL18728523 | 0.75 | EGFR (0.35) | EGFRLPLLIPGJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981839-B1 | COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS | PROMEGA CORP (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2024-02-22 | — | — | US | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | EGFR 4677/4885LPL 368/4885LIPG 1031/4885 |
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | EGFR 4677/4885LPL 368/4885LIPG 1031/4885 |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | EGFR 4677/4885LPL 368/4885LIPG 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.